WIN 52035-dependent human rhinovirus 16: Assembly deficiency caused by mutations near the canyon surface

Journal of Virology

Volumn 72, Issue 2, 1998, Pages 1210-1218

  Wang, Wensheng ^a,b   Lee, Wai Ming ^a   Mosser, Anne G ^a   Rueckert, Roland R ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; UNCLASSIFIED DRUG; WIN 52035;

ANTIVIRAL ACTIVITY; ARTICLE; DOSE RESPONSE; HUMAN RHINOVIRUS; MUTATION; PRIORITY JOURNAL; VIRUS ASSEMBLY; VIRUS CAPSID;

EID: 0031907562     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.2.1210-1218.1998     Document Type: Article

References (49)

1. Air, G. M. 1979. Nucleotide sequence coding for the "signal peptide" and N terminus of the hemagglutinin from an Asian (H2N2) strain of influenza virus. Virology 97:468-472.
2. Al-Nakib, W., P. G. Higgins, G. I. Barrow, D. A. Tyrrell, K. Andries, G. Vanden Bussche, N. Taylor, and P. A. Janssen. 1989. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob. Agents Chemother. 33:522-525.
3. Andries, K. 1995. Anti-picornaviral agents, p. 287-319. In D. J. Jeffries and E. DeClercq (ed.), Antiviral chemotherapy. John Wiley & Sons, New York, N. Y.
4. Bush, R. K., W. Busse, D. Flaherty, D. Warshauer, E. C. Dick, and C. E. Reed. 1978. Effects of experimental rhinovirus 16 infection on airways and leukocyte function in normal subjects. J. Allergy Clin. Immunol. 61:80-87.
5. 1 after in vitro incubation with rhinovirus 16. Am. Rev. Respir. Dis. 122:641-646.
6. Calhoun, W. J., C. A. Swenson, E. C. Dick, L. B. Schwartz, R. F. Lemanske, Jr., and W. W. Busse. 1991. Experimental rhinovirus 16 infection potentiates histamine release after antigen bronchoprovocation in allergic subjects. Am. Rev. Respir. Dis. 144:1267-1273.
7. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
8. Chow, M., R. Basavappa, and J. M. Hogle. 1997. The role of conformational transitions in poliovirus pathogenesis, p. 157-186. In W. Chiu, R. M. Burnett, and R. L. Garcea (ed.), Structural biology of viruses. Oxford University Press, New York, N.Y.
9. Colonno, R. J., J. H. Condra, S. Mizutani, P. L. Callahan, M.-E. Davis, and M. A. Murcko. 1988. Evidence for the direct involvement of the rhinovirus canyon in receptor binding. Proc. Natl. Acad. Sci. USA 85:5449-5453.
10. Colston, E., and V. R. Racaniello. 1994. Soluble receptor-resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor. EMBO J. 13:5855-5862.
11. Couch, R. B. 1990. Rhinoviruses, p. 607-629. In B. N. Fields, D. M. Knipe, R. M. Chanock, et al. (ed.), Virology, 2nd ed. Raven Press, New York, N.Y.
12. D'Alessio, D. J., J. A. Peterson, C. R. Dick, and E. C. Dick. 1976. Transmission of experimental rhinovirus colds in volunteer married couples. J. Inlect. Dis. 133:28-36.
13. Dick, E. C., and S. L. Inhorn. 1992. Rhinoviruses, p. 1507-1532. In R. D. Feigin and J. D. Cherry (ed.), Textbook of pediatric infection diseases, 3rd ed. W. B. Saunders Co., Philadelphia, Pa.
14. Eggers, H. J. 1977. Selective inhibition of uncoating of echovirus 12 by rhodanine. Virology 78:241-252.
15. Filman, D. J., R. Syed, M. Chow, A. J. Macadam, P. D. Minor, and J. M. Hogle. 1989. Structural factors that control conformational transitions and scrotype specificity in type 3 poliovirus. EMBO J. 8:1567-1579.
16. Fox, M. P., M. J. Otto, and M. A. McKinlay. 1986. The prevention of rhinovirus and poliovirus uncoating by WIN 51711: a new antiviral drug. Antimicrob. Agents Chemother. 30:110-116.
17. Greve, J. M., G. Davis, A. M. Meyer, C. P. Forte, S. C. Yost, C. W. Marlor, M. E. Kamarck, and A. McClelland. 1989. The major human rhinovirus receptor is ICAM-1. Cell 56:839-847.
18. Gwaltney, J. M., Jr. 1989. Rhinoviruses, p. 593-615. In A. S. Evans (ed.), Viral infection of humans. 3rd ed. Plenum Press, New York, N.Y.
19. Hadfield, A. T., W.-M. Lee, R. Zhao, M. A. Oliveira, I. Minor, R. R. Rueckert, and M. G. Rossmann. 1997. The refined structure of human rhinovirus 16 at 2.15 A resolution: implications for the viral life cycle. Structure 5:427-441.
20. Heinz, B. A., R. R. Rueckert, D. A. Shepard, F. J. Dutko, M. A. McKinlay, M. Fancher, M. G. Rossmann, J. Badger, and T. J. Smith. 1989. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J. Virol. 63:2476-2485.
21. Heinz, B. A., D. A. Shepard, and R. R. Rueckert. 1990. Escape mutants analysis of a drug-binding site can be used to map functions in the rhinovirus capsid, p. 173-186. In G. Laver and G. Air (ed.), Use of X-ray crystallography in the design of antiviral agents. Academic Press, New York, N.Y.
22. Hogle, J. M., M. Chow, and D. J. Filman. 1985. Three-dimensional structure of poliovirus at 2.9 A resolution. Science 229:1358-1365.
23. Kim, S., T. J. Smith, M. S. Chapman, M. G. Rossmann, D. C. Pevear, F. J. Dutko, P. J. Felock, G. D. Diana, and M. A. McKinlay. 1989. Crystal structure of human rhinovirus serotype 1A (HRV1A). J. Mol. Biol. 210:91-111.
24. Kunkel, T. A., J. D. Roberts, and R. A. Zakour. 1987. Rapid and efficient site-directed mutagenesis without phenotypic selection. Methods Enzymol. 154:367-382.
25. Lee, W.-M. Unpublished data.
26. Lee, W.-M., S. S. Monroe, and R. R. Rueckert. 1993. Role of maturation cleavage in infectivity of picornaviruses: activation of an infectosome. J. Virol. 67:2110-2122.
27. Lee, W.-M., W. Wang, and R. R. Rueckert. 1994. Complete sequence of the RNA genome of human rhinovirus 16, a clinically useful common cold virus belonging to the ICAM-1 receptor group. Virus Genes 9:177-181.
28. Lee, W.-M., W. Wang, and R. R. Rueckert. 1996. Is pocket factor required to activate assembly of picornaviral capsids?, p. 144. In Scientific Program & Abstracts of the American Society for Virology 15th Annual Meeting. University of Western Ontario, London, Ontario, Canada.
29. Lee, W.-M., et al. Unpublished data.
30. Lemanske, R. F., Jr., E. C. Dick, C. A. Swenson, R. F. Vrtis, and W. W. Busse. 1989. Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. J. Clin. Invest. 83:1-10.
31. Macadam, A. J., C. Arnold, J. Howlett, A. John, S. Marsden, F. Taffs, P. Reeve, N. Hamada, K. Wareham, J. Almond, et al. 1989. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 172:408-414.
32. Macadam, A. J., G. Ferguson, C. Arnold, and P. D. Minor. 1991. An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain. J. Virol. 65:5225-5231.
33. McKinlay, M. A., F. J. Dutko, D. C. Pevear, M. G. Woods, G. D. Diana, and M. G. Rossmann. 1990. Rational design of antipicornavirus agents, p. 366-372. In M. A. Brinton and F. X. Heinz (ed.), New aspects of positive-strand RNA viruses. American Society for Microbiology, Washington, D.C.
34. Medappa, K. C., C. McLean, and R. R. Rueckert. 1971. On the structure of rhinovirus 1A. Virology 44:259-270.
35. Meschievitz, C. K., S. B. Schultz, and E. C. Dick. 1984. A model for obtaining predictable natural transmission of rhinoviruses in human volunteers. J. Infect. Dis. 150:195-201.
36. Mosser, A. G., and R. R. Rueckert. 1996. Capsid-binding agents, p. 13-40. In D. D. Richman (ed.), Antiviral drug resistance. John Wiley & Sons Ltd., Chichester, England.
37. Mosser, A. G., and R. R. Rueckert. 1993. WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present. J. Virol. 67:1246-1254.
38. Mosser, A. G., J.-Y. Sgro, and R. R. Rueckert. 1994. Distribution of drug resistant mutations in type 3 poliovirus identifies three regions involved in uncoating functions. J. Virol. 68:8193-8201.
39. Oliveira, M. A., R. Zhao, W.-M. Lee, M. J. Kremer, I. Minor, R. R. Rueckert, G. D. Diana, D. C. Pevear, F. J. Dukto, M. A. McKinlay, and M. G. Rossmann. 1993. The structure of human rhinovirus 16. Structure 1:51-68.
40. Racaniello, V. R. 1996. Early events in poliovirus infection. Virus-cell interactions. Proc. Natl. Acad. Sci. USA 93:11378-11381.
41. Rossmann, M. G., E. Arnold, J. W. Erickson, E. A. Frankenberger, J. P. Griffith, H.-J. Hecht, J. E. Johnson, G. Kamer, M. Luo, A. G. Mosser, R. R. Rueckert, B. Sherry, and G. Vriend. 1985. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 317: 145-153.
42. Rueckert, R. R. 1996. Picornavirus structure and multiplication, p. 609-654. In B. N. Fields, D. M. Knipe, P. M. Howley, et al. (ed.), Virology, 3rd ed. Raven Press, Ltd., New York, N.Y.
43. Shepard, D. A., B. A. Heinz, and R. R. Rueckert. 1993. WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14. J. Virol. 67:2245-2254.
44. Sherry, B., and R. Rueckert. 1985. Evidence for at least two dominant neutralization antigens on human rhinovirus 14. J. Virol. 53:137-143.
45. Smith, T. J., M. J. Kremer, M. Luo, G. Vriend, E. Arnold, G. Kamer, M. G. Rossman, M. A. McKinlay, G. D. Diana, and M. J. Otto. 1986. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science 233:1286-1293.
46. Smith, T. J., M. H. Olsen, R. H. Cheng, E. S. Chase, and T. S. Baker. 1993. Structure of a human rhinovirus-bivalently bound antibody complex: implications for viral neutralization and antibody flexibility. Proc. Natl. Acad. Sci. USA 90:7015-7018.
47. Staunton, D. E., V. J. Merluzzi, R. Rothlein, R. Barton, S. D. Marlin, and T. A. Springer. 1989. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell 56:849-853.
48. Yin, F. H., and N. B. Lomax. 1983. Host range mutants of human rhinovirus in which nonstructural proteins are altered. J. Virol. 48:410-418.
49. Zeichhardt, H., M. J. Otto, M. A. McKinlay, P. Willingmann, and K.-O. Habermehl. 1987. Inhibition of poliovirus uncoating by disoxaril. Virology 160:281-285.